ACE and systemic sclerosis: To date, caution is needed when prescribing ACE-inhibitors to SSc patients who are at an high risk of developing scleroderma renal crisis, since a previous ACE-inhibitors therapy has been associated with a worst outcome in patient with this dramatic complication.[58]